International Journal of Rheumatic Diseases最新文献

{"title":"The Role of TYK2 Inhibitors in the Evolving Landscape of Rheumatologic and Dermatologic Treatment","authors":"I-Chang Lai, Yung-Heng Lee, Po-Cheng Shih, Meng-Che Wu","doi":"10.1111/1756-185X.70354","DOIUrl":"https://doi.org/10.1111/1756-185X.70354","url":null,"abstract":"<p>Tyrosine kinase 2 (TYK2) is a non-receptor tyrosine kinase and a key member of the Janus kinase (JAK) family, playing an essential role in the intracellular signaling of several cytokine pathways. Specifically, TYK2 mediates the signal transduction of interleukin-12 (IL-12), interleukin-23 (IL-23), and type I interferons (IFN-α/β), which are crucial regulators of innate and adaptive immune responses. These pathways are central to the pathogenesis of multiple autoimmune and inflammatory diseases, including psoriasis, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), and inflammatory bowel disease (IBD) [<span>1, 2</span>]. Unlike conventional JAK inhibitors, which target the active catalytic domain (JH1 domain) and broadly suppress multiple cytokine pathways, TYK2 inhibitors function through selective allosteric inhibition of the regulatory JH2 (pseudokinase) domain. This unique mechanism allows for precise modulation of TYK2 activity without directly affecting the ATP-binding site, thereby reducing off-target inhibition of JAK1, JAK2, and JAK3 [<span>2</span>]. By preserving partial physiological cytokine signaling, TYK2 inhibitors demonstrate a potentially improved safety profile compared to broader JAK inhibitors, particularly in terms of infection risk, malignancy concerns, and cardiovascular adverse events [<span>1, 3</span>].</p><p>From a clinical perspective, TYK2 inhibitors have emerged as promising therapeutic agents with an improved safety profile compared to conventional JAK inhibitors. Deucravacitinib, the first FDA-approved allosteric TYK2 inhibitor, has demonstrated efficacy in the treatment of moderate-to-severe plaque psoriasis, with ongoing trials exploring its potential in PsA and SLE [<span>4-10</span>]. Other TYK2 inhibitors, such as Brepocitinib and Ropsacitinib, are in earlier phases of clinical development and are being investigated for a range of autoimmune conditions [<span>11-20</span>]. This editorial aims to review the evidence-based medicine (EBM) level of TYK2 inhibitors across different autoimmune and dermatologic indications, compare their clinical positioning relative to biologic agents such as IL-17 and IL-23 inhibitors, and discuss the existing unmet needs and future research directions for TYK2-targeted therapies.</p><p>TYK2 inhibitors have been extensively studied across various immune-mediated diseases, with different levels of evidence supporting their use (Table 1). Among the available agents, Deucravacitinib has the most robust clinical data, particularly in psoriasis, where multiple Phase III trials confirm its efficacy, earning it Level 1A evidence [<span>4-8</span>]. Meanwhile, other TYK2 inhibitors such as Brepocitinib and Ropsacitinib remain in earlier phases of development, with supporting data primarily from Phase II trials, resulting in Level 2A or lower evidence across different indications [<span>11-20</span>].</p><p>In psoriasis, Deucravacitinib's FDA approval is backed by strong ","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70354","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Calcitonin Gene-Related Peptide on Cartilage in Osteoarthritis","authors":"Yucan Ju,&nbsp;Leyao Shen,&nbsp;Qiang Huang,&nbsp;Zeyu Huang","doi":"10.1111/1756-185x.70357","DOIUrl":"https://doi.org/10.1111/1756-185x.70357","url":null,"abstract":"<div>\u0000 \u0000 <p>Osteoarthritis (OA) is the most common age-related joint disease, which affects articular cartilage and joint structures, causing severe pain and disability. Owing to limited understanding of the underlying disease pathogenesis, there are currently no disease-modifying drugs for OA. Recent studies have demonstrated that calcitonin gene-related peptide (CGRP) plays an important role in OA synovial inflammation. Here, we first provide a fundamental basis for the physiological and pathological effects of CGRP in cartilage. Then we summarize current evidence of CGRP's roles in OA-affected tissues. We then focus on the potential innovative strategies for targeting CGRP to enhance cartilage regeneration. Further research into CGRP's role in OA may have broader implications in the understanding of OA pathogenesis, the standardization of biomarker detection, and the development of novel therapeutic routes for the prevention and management of OA.</p>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients With IgA Vasculitis and Kawasaki Disease Show Dysregulated Interferon Signature","authors":"Sevki Erdem Varol,&nbsp;Cisem Cinar,&nbsp;Nihan Burtecene,&nbsp;Sezgin Sahin,&nbsp;Mehmet Yildiz,&nbsp;Kenan Barut,&nbsp;Haluk Cokugras,&nbsp;Sinem Firtina,&nbsp;Ozgur Kasapcopur,&nbsp;Ayca Kiykim","doi":"10.1111/1756-185X.70349","DOIUrl":"https://doi.org/10.1111/1756-185X.70349","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>IgA vasculitis (IgAV) and Kawasaki disease (KD) are the most common forms of childhood vasculitis. Although various factors such as viral infections, genetic factors, and environmental factors are involved in the development of both diseases, their pathogenesis remains unclear. The interferon (IFN) signature, which reflects the activation of type I IFN signaling pathways, is a diagnostic and prognostic tool that contributes significantly to the pathogenesis and management of autoimmune diseases. In our study, we aimed to investigate the role of the IFN signature in patients with IgAV and KD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>Thirty-two children with IgAV and four patients diagnosed with KD were included in the study. Serum levels of IL-1, IL-6, IL-8, IL-10, IL-17, IL-18, TNF-α, TNF-R1, TNF-R2, and IFN-gamma were analyzed in the serum samples of all participants, and the expression of IFN-related genes (<i>STAT1, IFI27, IFI44, IFI44L, IFIT1</i>, and <i>RSAD2</i>) was assessed in the patients and healthy controls (<i>n</i> = 26) to calculate the IFN score by RT-PCR method.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A significant increase in the expression of three genes (<i>IFIT1, IFI44,</i> and <i>IFI27</i>) and decreased expression of the other three genes (<i>RSAD2, STAT1</i>, and <i>IFI44L</i>) was found in patients with IgAV and KD compared to the control group. Significantly higher IFN scores (IFN &gt; 3) were found in patients with gastrointestinal involvement, in patients who required corticosteroid therapy, and in patients who had to be hospitalized. No significant difference in IFN levels was found between patients with and without renal involvement. Significantly higher serum IL-1 levels were found in patients with gastrointestinal symptoms with IgAV. High IFN scores were found in three out of four patients diagnosed with KD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A dysregulated type 1 IFN signature was found in patients with IgAV and KD compared to the control group. A significantly increased risk of gastrointestinal involvement required corticosteroid therapy, and hospitalization was observed in patients diagnosed with IgAV who had high IFN levels. This underlines the idea that the IFN score could serve as a crucial prognostic indicator.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70349","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Risk Factors for Lupus Nephritis in Tunisian Patients With Systemic Lupus Erythematosus","authors":"Mourad Elghali,&nbsp;Imene Chaabane,&nbsp;Marwa Cherichi,&nbsp;Mahbouba Jguirim,&nbsp;Nabil Sakly,&nbsp;Sonia Hammami","doi":"10.1111/1756-185X.70348","DOIUrl":"https://doi.org/10.1111/1756-185X.70348","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Two Cases of Autoimmune/Inflammatory Syndrome Induced by Adjuvants","authors":"Karlygash Karina,&nbsp;Lina Zaripova,&nbsp;Bayan Ainabekova,&nbsp;Argul Issilbayeva,&nbsp;Nurzhan Asanov,&nbsp;Dinara Sadykova,&nbsp;Diana Makimova","doi":"10.1111/1756-185X.70350","DOIUrl":"https://doi.org/10.1111/1756-185X.70350","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of Juvenile Dermatomyositis—What We Know and What More Is Needed?","authors":"Dev Desai,&nbsp;Latika Gupta,&nbsp;Pandiarajan Vignesh","doi":"10.1111/1756-185X.70347","DOIUrl":"https://doi.org/10.1111/1756-185X.70347","url":null,"abstract":"<p>Juvenile idiopathic inflammatory myopathies (JIIMs) are a heterogeneous group of immune-mediated disorders—including Juvenile Dermatomyositis (JDM), Juvenile Polymyositis (JPM), immune-mediated necrotizing myositis, myositis associated with other connective tissue diseases, and rare disorders classified under the unified spectrum of idiopathic inflammatory myopathies (IIMs).</p><p>The estimated incidence of IIM varies from 1.6 to 19/million/year, and estimated prevalence varyies from 2.4 to 33.8/100000/year [<span>1</span>]. For JDM, the form of JIIM for which most estimates are available, the incidence varies from 1.9 to 3.2/million children/year [<span>2-4</span>]. The exact etiological basis of JIIMs is not yet known, but studies have found associations with several environmental triggers such as ultraviolet (UV) light exposure, air pollution, and a variety of infectious triggers. Genetic associations with HLA haplotypes have also been identified [<span>5, 6</span>]. Historically, JIIMs had a grim prognosis with a chronic and severe course, and as many as a third of all patients succumbing to the disease [<span>7</span>]. With advances in treatment, the prognosis for JIIMs has significantly improved, but mortality rates in JIIM patients remain higher than that in the general population [<span>6</span>], and most patients are seen to have some extent of disease damage [<span>8</span>]. Even among rheumatological disorders, JIIMs are rare, chronic disorders with patients requiring long-term management and rehabilitation at specialist centers. A better understanding of the epidemiology of the JIIMs can help in estimating the burden of disease, which can influence public health policy toward provision of healthcare facilities for these patients. Moreover, studying epidemiological trends over time can contribute toward recognition of risk factors, some of which may be modifiable. Epidemiological studies can also help guide future research and public health interventions [<span>9</span>].</p><p>Nossent et al. conducted a 30-year population-based retrospective study of 40 JIIM patients under 18 years in Western Australia, finding an annual incidence of 2.52/million children, with JDM at 2.02/million, female predominance, and a 94.9% 10-year survival rate. Compared with JIA controls, JIIM patients had significantly higher rates of serious infections, with nonsignificant increases in thromboembolic disease, ILD, osteoporosis, and pregnancy complications. Nossent et al.'s study makes a significant contribution by providing Australian population-based JIIM incidence data and enabling outcome comparisons with JIA as a control group. The extended median follow-up of over 10 years offers valuable insights into the long-term complications and functional impacts of JIIM.</p><p>As the understanding of JIIMs has evolved over time, it has been seen that different autoantibodies confer different clinical phenotypes and also have a significant bearing on outcom","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1756-185X.70347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Vertebrae in Patients With Ankylosing Spondylitis Using Hounsfield Unit Values","authors":"Junya Hasegawa,&nbsp;Mochihito Suzuki,&nbsp;Kenji Kishimoto,&nbsp;Ryo Sato,&nbsp;Yusuke Ohno,&nbsp;Takaya Sugiura,&nbsp;Hiroto Yamamoto,&nbsp;Kenya Terabe,&nbsp;Shuji Asai,&nbsp;Shiro Imagama","doi":"10.1111/1756-185X.70332","DOIUrl":"https://doi.org/10.1111/1756-185X.70332","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate vertebral Hounsfield Unit (HU) values on computed tomography (CT) in patients with ankylosing spondylitis (AS) compared to patients without AS and to examine differences in HU values between ankylosed and nonankylosed vertebrae in patients with AS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional study included 34 patients with AS and 73 patients without AS who underwent spinal CT between 2004 and 2022. HU values were measured from C3 to L5 in patients with AS and from L1 to L5 in patients without AS. Propensity score (PS) matching based on age and sex was performed to compare HU values between groups. Additionally, HU values were compared between ankylosed and nonankylosed vertebrae within the AS group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After PS matching, vertebral HU values were significantly lower in patients with AS than in patients without AS (136.4 vs. 197.1, <i>p</i> = 0.009). Among patients with AS, HU values were highest in the cervical spine, followed by the thoracic and lumbar regions. Ankylosed vertebrae showed significantly lower HU values than nonankylosed vertebrae across all spinal levels (<i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Vertebral HU values were lower in patients with AS compared to age- and sex-matched patients without AS. HU values were highest in the cervical spine, and ankylosed vertebrae consistently exhibited lower HU values than nonankylosed vertebrae across all spinal regions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Accuracy of Screening for Symptoms of Anxiety and Depression Among Patients With Rheumatoid Arthritis in Private Physiotherapy Practices","authors":"Davy Vancampfort,&nbsp;Isabel Zwahlen,&nbsp;Veerle Gillis,&nbsp;Emanuel Brunner,&nbsp;Tine Van Damme","doi":"10.1111/1756-185X.70335","DOIUrl":"https://doi.org/10.1111/1756-185X.70335","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulation of Wnt/β-Catenin Signaling by STAT3 Inhibition Restores Myogenic Capacity in Sarcopenia","authors":"Suhong Zhang,&nbsp;Xin Tao,&nbsp;Minghui Fu,&nbsp;Yue Li,&nbsp;Gongbing Tu,&nbsp;Dianfu Zhang,&nbsp;Liping Yin","doi":"10.1111/1756-185X.70340","DOIUrl":"https://doi.org/10.1111/1756-185X.70340","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sarcopenia is a progressive disorder characterized by loss of skeletal muscle mass, strength, and function. Although STAT3 is known to regulate myogenic differentiation, its role in sarcopenia remains unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>STAT3 expression was assessed in skeletal muscle samples from sarcopenia patients and nonsarcopenic controls, as well as aged SAMP8 mice. C2C12 myoblasts were used to investigate the effects of STAT3 on proliferation and myogenic differentiation using gain- and loss-of-function approaches. The role of the Wnt/β-catenin pathway was examined using pathway-specific assays. In vivo, siRNA-mediated STAT3 knockdown was performed in aged SAMP8 mice to evaluate effects on muscle phenotype and endurance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>STAT3 expression was significantly upregulated in muscle tissues from sarcopenia patients and aged mice, correlating with increased expression of the atrophy marker MuRF-1. STAT3 levels also rose during C2C12 cell differentiation. STAT3 overexpression suppressed C2C12 proliferation and myogenic differentiation, whereas knockdown enhanced both processes. Mechanistically, STAT3 inhibited Wnt/β-catenin signaling, reducing the expression of myogenic markers. In vivo, STAT3 silencing in aged mice increased muscle mass, improved treadmill performance, and decreased muscle atrophy markers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>STAT3 impairs myogenic proliferation and differentiation by negatively regulating the Wnt/β-catenin pathway, contributing to sarcopenia progression. Targeting STAT3 may serve as a promising therapeutic strategy for restoring muscle regeneration and function in sarcopenia.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: Chalk-Like Synovial Fluid and Calcified Synovium in Systemic Sclerosis Overlapping With Rheumatoid Arthritis Stabilized by Rituximab","authors":"Amphay Khounthep,&nbsp;Punthip Thummaroj,&nbsp;Ajanee Mahakkanukrauh,&nbsp;Siraphop Suwannaroj,&nbsp;Chingching Foocharoen","doi":"10.1111/1756-185X.70352","DOIUrl":"https://doi.org/10.1111/1756-185X.70352","url":null,"abstract":"","PeriodicalId":14330,"journal":{"name":"International Journal of Rheumatic Diseases","volume":"28 7","pages":""},"PeriodicalIF":2.4,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144519993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}